

PRESS RELEASE

APHARM SRL AND LABORATOIRES EXPANSCIENCE ANNOUNCE DISTRIBUTION AGREEMENT FOR HYALEXO® MONO AND HYALEXO® CROSS, NOVEL FORMULATIONS FOR INTRA-ARTICULAR INJECTIONS, BASED ON HYALURONIC ACID.

Arona, Italy and Paris, France, September 2, 2021

Apharm s.r.l. - subsidiary of Biofarma Group, CDMO leader in the development, production and packaging of MD, nutraceuticals and food supplements and Laboratoires Expanscience, a leading independent French pharmaceutical and dermo-cosmetics laboratory developing and commercializing innovative osteoarthritis products, announced today the signing of a distribution agreement for 2 new hyaluronic acid mono injections which are novel proprietary formulations, for intra-articular injection in Orthopaedic procedures.

Under the agreement, Apharm has appointed Laboratoires Expanscience as distributor in France for both products which are already approved Medical Devices and will be sold under the Hyalexo® Cross and Hyalexo® Mono brand names. Launches are planned in September 2021.

Hyalexo® Mono's intended use is in human therapy as a temporary synovial fluid replacement for patients affected by degenerative or mechanical arthropathy which causes pain or reduced mobility.

Hyalexo® Cross is indicated for pain and reduced mobility due to traumatic or degenerative deformities of the knee joint and other synovial joints.

Both products are administered by intra-articular injection in adult population.

"This agreement sets an important milestone for Apharm within the Biofarma Group," commented Biofarma Group CEO Maurizio Castorina "We are very pleased to add Laboratoires Expanscience as an important strategic partner, consolidating our long experience in novel hyaluronic acid formulations for intra-articular injections and other indications." He added "This is the first agreement for our newest formulation, crosslinked Hyaluronic acid, for a major market France. We are looking forward to developing a strong relationship with Laboratoires Expanscience"

Expanscience Rheumatology COO Julien Zeller added "This new partnership with Apharm is very important for Laboratoires Expanscience. It reinforces our long-term commitment to improve the quality of life for millions of people suffering from osteoarthritis. The launch of these two single-injection hyaluronic acids with innovative formulas will enable Expanscience to complete its offer for treating osteoarthritis in its home country. We are confident Hyalexo® Mono and Hyalexo® Cross will meet both patients' and doctors' expectations."

About Laboratoires Expanscience

In 2020, Laboratoires Expanscience – a French independently-owned pharmaceutical and dermo-cosmetics laboratory –generated a turnover of €250.2 M, 73% of which out of France.

Its solid reputation as an innovator and as a specialist both in skin care and treatment of osteoarthritis is based on its leading brands – Mustela® and Piasclédine® 300 - in particular.

With its Rheumatology business, Laboratoires Expanscience aims at reconciling aging and quality of life and helps millions of individuals who suffer from osteoarthritis to continue doing what they love as long as possible. Expanscience designs safe therapeutic solutions but also develops services that help patients take charge of their illness and is mobilized along with healthcare professionals and society as a whole to improve prevention, diagnosis and compliance.

Expanscience's positive impact on society and the environment is recognized by the international B Corp label.

Laboratoires Expanscience in figures

- Creation: 1950
- 2020 turnover: €250.2 M
- 102 distributing countries
- 14 subsidiaries
- 1043 employees
- 52 million products manufactured in 2020
- Activities: Dermo-Cosmetics, Dermatology, Rheumatology, Cosmetic active ingredients

For more information, please visit www.expanscience.com or contact: Agence JIN - Camille Billiemaz | cbilliemaz@jin.fr | +33 6 31 58 82 37

About Biofarma Group and Apharm s.r.l.

Biofarma Group is the leading Italian group of companies that develops, produces and packages food supplements, medical devices, drugs with probiotics and cosmetics, exclusively for third parties.

With 4 production sites spread between Friuli Venezia Giulia, Veneto and Lombardy, Biofarma Group offers customized solutions, from idea development to the finished product and a broad catalogue of products ready to be distributed, some of them with clinical studies and patented.

Innovation and competence combined with investments in production processes, cutting-edge machinery and human capital, allow the Group to be, on the Italian and international market, a highly attractive and competitive reference point in the development and manufacture of Health-Care and Beauty Care products ([www. biofarmagroup.it](http://www.biofarmagroup.it)).

Apharm s.r.l. is subsidiary of Biofarma Group.

It is a dynamic Italian based pharmaceutical company whose core business is the research and development of new products and registration of innovative patents that are licensed on a global basis. Apharm operates in a number of therapeutic area but is most active in the fields of gastroenterology, orthopaedic and dermatology. Constantly committed to improve people's life quality in terms of health and wellbeing, Apharm carries out an active role in discovering and treating pathologies of high social impact.

For more information, please visit www.biofarmagroup.it or contact:

Mr. Paolo Pizzoni, Director and co-founder of Apharm (paolo.pizzoni@biofarmagroup.it).

Mr. Valerio Ferri, Global Sales Director at Biofarma Group (ferri.valerio@biofarmagroup.it)

The Trademarks Hyalexo® Mono and Hyalexo® Cross are property of Laboratoires Expanscience.